佐力药业
(300181)
| 流通市值：101.65亿 | | | 总市值：118.25亿 |
| 流通股本：6.03亿 | | | 总股本：7.01亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 824,425,237.08 | 2,577,878,166.87 | 2,044,879,347.76 | 1,428,254,689.36 |
| 营业收入 | 824,425,237.08 | 2,577,878,166.87 | 2,044,879,347.76 | 1,428,254,689.36 |
| 二、营业总成本 | 623,213,469.79 | 2,050,169,103.69 | 1,611,761,923.04 | 1,125,110,666.79 |
| 营业成本 | 322,376,359.19 | 1,006,601,043.75 | 785,107,058.96 | 533,860,844.03 |
| 税金及附加 | 6,322,257.02 | 29,056,520.72 | 21,218,914.96 | 16,016,318.02 |
| 销售费用 | 256,281,862.95 | 838,702,179.12 | 684,123,230.33 | 488,276,831.43 |
| 管理费用 | 23,478,495.24 | 110,378,725.35 | 77,419,474.48 | 53,428,676.51 |
| 研发费用 | 13,423,922.11 | 71,938,052.87 | 50,804,515.11 | 39,171,362.72 |
| 财务费用 | 1,330,573.28 | -6,507,418.12 | -6,911,270.8 | -5,643,365.92 |
| 其中:利息费用 | 2,784,981.17 | 9,289,184.83 | 6,555,189.22 | 4,100,316.58 |
| 其中:利息收入 | 1,488,351.86 | 15,953,231.8 | 13,574,239.23 | 9,806,179.89 |
| 加:投资收益 | -292,960.5 | -662,074.01 | -481,763.27 | -16,397.46 |
| 资产处置收益 | - | 352,220.71 | 343,312.3 | 233,518.16 |
| 资产减值损失(新) | 686,021.49 | -12,198,929.71 | - | - |
| 信用减值损失(新) | -9,748,235.25 | -6,566,372.99 | -10,784,061.03 | -6,998,316.53 |
| 其他收益 | 23,926,335.87 | 100,653,614.62 | 81,748,620.64 | 57,833,550.81 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 215,782,928.9 | 609,287,521.8 | 503,943,533.36 | 354,196,377.55 |
| 加:营业外收入 | 70,331.63 | 708,358.65 | 589,405.75 | 322,374.72 |
| 减:营业外支出 | 2,116,208.65 | 13,303,138.51 | 9,745,927.11 | 10,249,346.24 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 213,737,051.88 | 596,692,741.94 | 494,787,012 | 344,269,406.03 |
| 减:所得税费用 | 30,350,870.36 | 80,734,655.22 | 67,404,728.72 | 44,421,055.19 |
| 六、净利润 | 183,386,181.52 | 515,958,086.72 | 427,382,283.28 | 299,848,350.84 |
| 持续经营净利润 | 183,386,181.52 | 515,958,086.72 | 427,382,283.28 | 299,848,350.84 |
| 归属于母公司股东的净利润 | 181,151,432.46 | 507,771,934.85 | 421,480,135.5 | 296,054,107.17 |
| 少数股东损益 | 2,234,749.06 | 8,186,151.87 | 5,902,147.78 | 3,794,243.67 |
| (一)基本每股收益 | 0.26 | 0.73 | 0.6 | 0.42 |
| (二)稀释每股收益 | 0.26 | 0.73 | 0.6 | 0.42 |
| 八、其他综合收益 | 122,157,526.18 | 56,170,995.22 | -33,438,805.14 | -32,134,019.23 |
| 归属于母公司股东的其他综合收益 | 113,000,598.02 | 51,960,417.42 | -30,932,232.31 | -29,725,253.15 |
| 九、综合收益总额 | 305,543,707.7 | 572,129,081.94 | 393,943,478.14 | 267,714,331.61 |
| 归属于母公司股东的综合收益总额 | 294,152,030.48 | 559,732,352.27 | 390,547,903.19 | 266,328,854.02 |
| 归属于少数股东的综合收益总额 | 11,391,677.22 | 12,396,729.67 | 3,395,574.95 | 1,385,477.59 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-28 | 2024-07-30 |
| 审计意见(境内) | | 标准无保留意见 | | |